Johnson & Johnson (NYSE:JNJ) Shares Down 1.7% – What’s Next?

Johnson & Johnson (NYSE:JNJ) fell 1.7% during mid-day trading on Tuesday . The stock traded as low as $229.08 and last traded at $230.37. 6,427,275 shares were traded during trading, a decline of 23% from the average session volume of 8,388,652 shares. The stock had previously closed at $234.34.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson’s DePuy Synthes unit struck an exclusive distribution deal for the NOVOSIS bone graft product in the U.S., Canada, and Australia, a small but potentially helpful growth catalyst for its MedTech business. Article Title
• Positive Sentiment: Several recent articles argue that J&J remains an attractive large-cap pharma name, citing its diversified pharma/MedTech mix, defensive business model, and “Dividend King” appeal. Article Title
• Positive Sentiment: Another piece highlights J&J’s innovation push through its new NJ Innovation Hub partnership, which could support longer-term pipeline and ecosystem development. Article Title
• Neutral Sentiment: Analysts continue to frame J&J as a value-and-quality name after strong Q1 results and raised guidance, suggesting fundamentals remain solid even after the latest move. Article Title
• Negative Sentiment: Fresh talc litigation remains the biggest overhang: a Minnesota jury included J&J in a $10.2 million mesothelioma verdict, adding to ongoing legal and reputational risk tied to asbestos-contaminated cosmetic talc products. Article Title
• Negative Sentiment: Broader healthcare weakness also weighed on sentiment, with the sector dragging on the Dow as investors rotated into other parts of the market. Article Title

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on JNJ. Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, April 15th. HSBC increased their price objective on shares of Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Rothschild & Co Redburn increased their price objective on shares of Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research report on Thursday, February 19th. Leerink Partners raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price objective on the stock in a research report on Wednesday, May 13th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $265.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Twenty investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $253.04.

Johnson & Johnson Trading Down 1.7%

The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The firm has a market capitalization of $554.55 billion, a P/E ratio of 26.63, a price-to-earnings-growth ratio of 2.29 and a beta of 0.27. The business’s 50-day moving average is $233.87 and its 200 day moving average is $223.88.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same period last year, the firm earned $2.77 EPS. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, analysts anticipate that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.3%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio is 60.12%.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds have recently added to or reduced their stakes in JNJ. AustralianSuper Pty Ltd boosted its holdings in Johnson & Johnson by 632.0% during the 3rd quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock worth $16,536,000 after acquiring an additional 77,000 shares during the last quarter. J.W. Cole Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 2.2% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock worth $24,278,000 after buying an additional 2,769 shares during the last quarter. Guinness Asset Management LTD boosted its holdings in shares of Johnson & Johnson by 0.4% in the 3rd quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock worth $251,216,000 after buying an additional 5,994 shares during the last quarter. Greenberg Financial Group purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $954,000. Finally, National Pension Service lifted its holdings in Johnson & Johnson by 3.2% during the third quarter. National Pension Service now owns 4,926,569 shares of the company’s stock valued at $913,484,000 after purchasing an additional 151,707 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.